Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8405942 | 0.90 | ACHE (0.35) | ACHEMBNL1RAPGEF4NQO2CYP3A4 | |
| SCHEMBL15496493 | 0.87 | ACHE (0.36) | ACHEMBNL1RAPGEF4CYP1A2CYP2A6 | |
| SCHEMBL30867032 | 0.82 | ACHE (0.42) | ACHERAPGEF4NQO2CYP3A4TSHR | |
| SCHEMBL5616902 | 0.82 | ACHE (0.42) | ACHERAPGEF4NQO2CYP3A4TSHR | |
| SCHEMBL30587865 | 0.82 | TSHR (0.41) | ACHENQO2CYP3A4TSHRMAPK1 | |
| SCHEMBL6012957 | 0.82 | TSHR (0.41) | ACHENQO2CYP3A4TSHRMAPK1 | |
| SCHEMBL10710404 | 0.82 | GPR84 (0.43) | GPR84 | |
| SCHEMBL8912022 | 0.78 | GPR84 (0.41) | GPR84 | |
| SCHEMBL543927 | 0.78 | TERT (0.41) | ACHENQO2CYP3A4TSHRMAPK1 | |
| SCHEMBL30943509 | 0.78 | TERT (0.41) | ACHENQO2CYP3A4TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884249-B2 | oxidizing a diol derivative with an oxidizing agent such as osmium tetraoxide to form 6,13-ethanopentacene-6,13-dione | CANON KABUSHIKI KAISHA (JP) | 2011-02-08 | — | — | US | disclosed |
| US-7884249-B2 | oxidizing a diol derivative with an oxidizing agent such as osmium tetraoxide to form 6,13-ethanopentacene-6,13-dione | CANON KABUSHIKI KAISHA (JP) | 2011-02-08 | — | — | US | disclosed |
| US-20090317753-A1 | BICYCLO COMPOUND, METHOD FOR PRODUCING PENTACENE AND A FILM THEREOF USING THE SAME, AND METHOD FOR PRODUCING BICYCLO COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090317753-A1 | BICYCLO COMPOUND, METHOD FOR PRODUCING PENTACENE AND A FILM THEREOF USING THE SAME, AND METHOD FOR PRODUCING BICYCLO COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2009-12-24 | — | — | US | disclosed |
| US-7601478-B2 | Bicyclo compound, method for producing fused aromatic compound using the same and method for forming film of the same | CANON KABUSHIKI KAISHA (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7601478-B2 | Bicyclo compound, method for producing fused aromatic compound using the same and method for forming film of the same | CANON KABUSHIKI KAISHA (JP) | 2009-10-13 | — | — | US | disclosed |
| US-7588959-B2 | Organic field effect transistor and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2009-09-15 | — | — | US | disclosed |
| US-7588959-B2 | Organic field effect transistor and method for producing the same | CANON KABUSHIKI KAISHA (JP) | 2009-09-15 | — | — | US | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317753-A1 | BICYCLO COMPOUND, METHOD FOR PRODUCING PENTACENE AND A FILM THEREOF USING THE SAME, AND METHOD FOR PRODUCING BICYCLO COMPOUND | C9, C5, RNF168 | ACHE 2064/4885GPR84 1747/4885MBNL1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.